Curaleaf Holdings, Inc.

The broader medical cannabis market is projected to grow at a 13.8% CAGR, reaching $59.45 billion by 2035. Favorable regulatory shifts, including potential Trump-era actions that have already driven a California cannabis company to a $1B valuation, could unlock significant federal-level tailwinds for Curaleaf's U.S. operations.

Despite optimism around regulatory reform, Curaleaf remains unprofitable and is not forecast to become profitable over the next three years. The stock's extreme volatility — with daily average swings exceeding 14% — reflects deep uncertainty about whether regulatory changes will materialize in time to rescue the company's deteriorating financials.

TipRanks' AI analyst highlights improving financial momentum, including a revenue rebound and positive operating and free cash flow, alongside better profitability metrics and refinancing progress. The most recent analyst rating carries a Buy designation with a C$15.00 price target, suggesting meaningful upside from current levels.

SimplyWallSt forecasts earnings to decline by an average of 25.3% per year over the next three years, with Curaleaf currently unprofitable and not expected to reach profitability within that horizon. Ongoing structural leverage constraints and a negative P/E ratio further undermine the case for a financial turnaround.

Curaleaf's stock is trading at an estimated 51.5% below its fair value, and 14 covering analysts are in good agreement that the stock price will rise approximately 21.9%. Technical indicators, including buy signals from both short- and long-term moving averages and a positive MACD, support a recovery thesis.

Despite apparent undervaluation, Curaleaf's share price has been highly volatile, trading within a wide horizontal range between roughly $1.06 and $1.64 over a three-month period. The stock's limited liquidity, negative earnings, and absence of dividend yield provide little fundamental anchor for a sustained price recovery.